1
|
Lahmy R, Hübner H, Schmidt MF, Lachmann D, Gmeiner P, König B. Photochromic Fentanyl Derivatives for Controlled μ-Opioid Receptor Activation. Chemistry 2022; 28:e202201515. [PMID: 35899620 PMCID: PMC9826449 DOI: 10.1002/chem.202201515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Indexed: 01/11/2023]
Abstract
Photoswitchable ligands as biological tools provide an opportunity to explore the kinetics and dynamics of the clinically relevant μ-opioid receptor. These ligands can potentially activate or deactivate the receptor when desired by using light. Spatial and temporal control of biological activity allows for application in a diverse range of biological investigations. Photoswitchable ligands have been developed in this work, modelled on the known agonist fentanyl, with the aim of expanding the current "toolbox" of fentanyl photoswitchable ligands. In doing so, ligands have been developed that change geometry (isomerize) upon exposure to light, with varying photophysical and biochemical properties. This variation in properties could be valuable in further studying the functional significance of the μ-opioid receptor.
Collapse
Affiliation(s)
- Ranit Lahmy
- Institute of Organic ChemistryDepartment of Chemistry and PharmacyUniversity of Regensburg93053RegensburgGermany
| | - Harald Hübner
- Department of Chemistry and PharmacyFriedrich Alexander University91052ErlangenGermany
| | - Maximilian F. Schmidt
- Department of Chemistry and PharmacyFriedrich Alexander University91052ErlangenGermany
| | - Daniel Lachmann
- Institute of Organic ChemistryDepartment of Chemistry and PharmacyUniversity of Regensburg93053RegensburgGermany
| | - Peter Gmeiner
- Department of Chemistry and PharmacyFriedrich Alexander University91052ErlangenGermany
| | - Burkhard König
- Institute of Organic ChemistryDepartment of Chemistry and PharmacyUniversity of Regensburg93053RegensburgGermany
| |
Collapse
|
2
|
Drakopoulos A, Moianos D, Prifti GM, Zoidis G, Decker M. Opioid ligands addressing unconventional binding sites and more than one opioid receptor subtype. ChemMedChem 2022; 17:e202200169. [PMID: 35560796 DOI: 10.1002/cmdc.202200169] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 05/11/2022] [Indexed: 11/10/2022]
Abstract
Opioid receptors (ORs) represent one of the most significant groups of G-protein coupled receptor (GPCR) drug targets and also act as prototypical models for GPCR function. In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and function, various (poly)pharmacological ligand design approaches have been performed. That is, besides classical ligands, a great number of bivalent ligands (i.e. aiming on two distinct OR subtypes), univalent heteromer-selective ligands and bitopic and allosteric ligands have been synthesized for the ORs. The scope of our review is to present the most important of the aforementioned ligands, highlight their properties and exhibit the current state-of-the-art pallet of promising drug candidates or useful molecular tools for the ORs.
Collapse
Affiliation(s)
- Antonios Drakopoulos
- University of Gothenburg: Goteborgs Universitet, Department of Chemistry and Molecular Biology, Kemigåden 4, 431 45, Göteborg, SWEDEN
| | - Dimitrios Moianos
- National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon, Department of Pharmacy, Panepistimiopolis-Zografou, 15771, Athens, GREECE
| | - Georgia-Myrto Prifti
- National and Kapodistrian University of Athens: Ethniko kai Kapodistriako Panepistemio Athenon, Department of Pharmacy, Panepistimiopolis-Zografou, 15771, Athens, GREECE
| | - Grigoris Zoidis
- National and Kapodistrian University of Athens, Department of Pharmaceutical Chemistry, Panepistimioupolis-Zografou, 15771, Athens, GREECE
| | - Michael Decker
- Julius-Maximilians-Universität Würzburg: Julius-Maximilians-Universitat Wurzburg, Institute of Pharmacy and Food Chemistry, Am Hubland, 97074, Würzburg, GERMANY
| |
Collapse
|
3
|
Rosier N, Grätz L, Schihada H, Möller J, Işbilir A, Humphrys LJ, Nagl M, Seibel U, Lohse MJ, Pockes S. A Versatile Sub-Nanomolar Fluorescent Ligand Enables NanoBRET Binding Studies and Single-Molecule Microscopy at the Histamine H 3 Receptor. J Med Chem 2021; 64:11695-11708. [PMID: 34309390 DOI: 10.1021/acs.jmedchem.1c01089] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The histamine H3 receptor (H3R) is considered an attractive drug target for various neurological diseases. We here report the synthesis of UR-NR266, a novel fluorescent H3R ligand. Broad pharmacological characterization revealed UR-NR266 as a sub-nanomolar compound at the H3R with an exceptional selectivity profile within the histamine receptor family. The presented neutral antagonist showed fast association to its target and complete dissociation in kinetic binding studies. Detailed characterization of standard H3R ligands in NanoBRET competition binding using UR-NR266 highlights its value as a versatile pharmacological tool to analyze future H3R ligands. The low nonspecific binding observed in all experiments could also be verified in TIRF and confocal microscopy. This fluorescent probe allows the highly specific analysis of native H3R in various assays ranging from optical high throughput technologies to biophysical analyses and single-molecule studies in its natural environment. An off-target screening at 14 receptors revealed UR-NR266 as a selective compound.
Collapse
Affiliation(s)
- Niklas Rosier
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany
| | - Lukas Grätz
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany
| | - Hannes Schihada
- Section of Receptor Biology & Signaling, Dept. of Physiology & Pharmacology, Karolinska Institutet, Solnavägen 1, Stockholm 171 77, Sweden
| | - Jan Möller
- Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany.,Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Straße 2, Würzburg 97070, Germany
| | - Ali Işbilir
- Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany.,Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Straße 2, Würzburg 97070, Germany
| | - Laura J Humphrys
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany
| | - Martin Nagl
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany
| | - Ulla Seibel
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany
| | - Martin J Lohse
- Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, Berlin 13125, Germany.,Institute of Pharmacology and Toxicology and Rudolf Virchow Center, University of Würzburg, Josef-Schneider-Straße 2, Würzburg 97070, Germany.,ISAR Bioscience Institute, Semmelweisstraße 5, Planegg 82152, Germany
| | - Steffen Pockes
- Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, Regensburg 93053, Germany.,Department of Neurology, University of Minnesota, 2101 6th Street SE, Minneapolis, Minnesota 55455, United States.,Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, United States
| |
Collapse
|
4
|
Borgarelli C, Klingl YE, Escamilla-Ayala A, Munck S, Van Den Bosch L, De Borggraeve WM, Ismalaj E. Lighting Up the Plasma Membrane: Development and Applications of Fluorescent Ligands for Transmembrane Proteins. Chemistry 2021; 27:8605-8641. [PMID: 33733502 DOI: 10.1002/chem.202100296] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Indexed: 12/16/2022]
Abstract
Despite the fact that transmembrane proteins represent the main therapeutic targets for decades, complete and in-depth knowledge about their biochemical and pharmacological profiling is not fully available. In this regard, target-tailored small-molecule fluorescent ligands are a viable approach to fill in the missing pieces of the puzzle. Such tools, coupled with the ability of high-precision optical techniques to image with an unprecedented resolution at a single-molecule level, helped unraveling many of the conundrums related to plasma proteins' life-cycle and druggability. Herein, we review the recent progress made during the last two decades in fluorescent ligand design and potential applications in fluorescence microscopy of voltage-gated ion channels, ligand-gated ion channels and G-coupled protein receptors.
Collapse
Affiliation(s)
- Carlotta Borgarelli
- Department of Chemistry, Molecular Design and Synthesis, KU Leuven Campus Arenberg Celestijnenlaan 200F -, box 2404, 3001, Leuven, Belgium
| | - Yvonne E Klingl
- Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium.,Laboratory of Neurobiology, VIB, Center for Brain &, Disease Research, VIB-KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium
| | - Abril Escamilla-Ayala
- Center for Brain & Disease Research, & VIB BioImaging Core, VIB-KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium.,Department of Neurosciences, Leuven Brain Institute, KU Leuven, Campus Gasthuisberg O&N5 - box 602 Herestraat 49, 3000, Leuven, Belgium
| | - Sebastian Munck
- Center for Brain & Disease Research, & VIB BioImaging Core, VIB-KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium.,Department of Neurosciences, Leuven Brain Institute, KU Leuven, Campus Gasthuisberg O&N5 - box 602 Herestraat 49, 3000, Leuven, Belgium
| | - Ludo Van Den Bosch
- Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium.,Laboratory of Neurobiology, VIB, Center for Brain &, Disease Research, VIB-KU Leuven Campus Gasthuisberg O&N5 -, box 602 Herestraat 49, 3000, Leuven, Belgium
| | - Wim M De Borggraeve
- Department of Chemistry, Molecular Design and Synthesis, KU Leuven Campus Arenberg Celestijnenlaan 200F -, box 2404, 3001, Leuven, Belgium
| | - Ermal Ismalaj
- Department of Chemistry, Molecular Design and Synthesis, KU Leuven Campus Arenberg Celestijnenlaan 200F -, box 2404, 3001, Leuven, Belgium
| |
Collapse
|
5
|
Drakopoulos A, Decker M. Development and Biological Applications of Fluorescent Opioid Ligands. Chempluschem 2020; 85:1354-1364. [DOI: 10.1002/cplu.202000212] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 05/30/2020] [Indexed: 12/24/2022]
Affiliation(s)
- Antonios Drakopoulos
- Pharmaceutical and Medicinal ChemistryInstitute of Pharmacy and Food ChemistryJulius Maximilian University of Würzburg 97074 Würzburg Germany
| | - Michael Decker
- Pharmaceutical and Medicinal ChemistryInstitute of Pharmacy and Food ChemistryJulius Maximilian University of Würzburg 97074 Würzburg Germany
| |
Collapse
|